
Merck to Acquire Verona Pharma, Adding First-in-Class COPD Drug Ohtuvayre to Pipeline
Merck, known as MSD outside the U.S. and Canada, announced that it will acquire Verona Pharma plc in a $10 billion deal, strengthening its presence in the respiratory disease space. The acquisition includes Verona’s lead asset, Ohtuvayre (ensifentrine), a …